The Quantellect read.As of Nov 19, 2026, 9 active firms cover BridgeBio Oncology Therapeutics, Inc: 9 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $13.00 to $29.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $21.11 sits 1073% above the current $1.80. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.42 next quarter toward $-2.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy9100%
Neutral00%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$21.11
+1072.8% upside
Average target across 9 active firms as of Nov 19, 2026 vs $1.80 current
Highest Target$29.00
Average Target$21.11
Lowest Target$13.00
Detailed analyst forecasts for BBOT
Showing 1–9 of 9 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 9 of 9 active firms rate BBOT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BBOT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.42
Range $-0.46 – $-0.27 · 10 analysts · -14% YoY
Next period, 10 analysts expect BridgeBio Oncology Therapeutics, Inc. to earn $-0.42 a share (range $-0.46 – $-0.27), versus $-0.49 a year earlier. Full-year consensus is $-2.20, growing to $-2.09 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 10 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering BridgeBio Oncology Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BBOT.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$25.00+1288.9% to target
Overall win rate
48%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #162
Buy
$25.00+1288.9% to target
Overall win rate
53%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$29.00+1511.1% to target
Overall win rate
42%
+ Follow
#4
John Newman
Canaccord Genuity · Rank #538
Buy
$20.00+1011.1% to target
Overall win rate
31%
+ Follow
#5
Sean Laaman
Morgan Stanley
Buy
$13.00+622.2% to target
Coverage
—
+ Follow
BBOT stock forecast FAQ
What is BBOT's average 12-month price target?+
The 9 active firms with a live target average $21.11 for BridgeBio Oncology Therapeutics, Inc. over the next 12 months, ranging from a $29.00 high to a $13.00 low, as of Nov 19, 2026.
Is BBOT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BBOT?+
The Street-high target is $29.00 (HC Wainwright & Co.), and the Street-low is $13.00 (Morgan Stanley). The average of all 9 active-firm targets is $21.11.
How many active Wall Street firms cover BBOT?+
9 active firms have a recognized rating on BridgeBio Oncology Therapeutics, Inc. as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BBOT?+
Among analysts who currently cover BBOT, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $25.00 target.
What is BridgeBio Oncology Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.42 per share (range $-0.46 – $-0.27) across 10 analysts. Full-year EPS is projected at $-2.20, rising to $-2.09 the following year.
How much revenue is BridgeBio Oncology Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading BBOT lately?+
As of Nov 19, 2026, 9 of 9 active firms rate BBOT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BBOT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.